Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kalaris Therapeutics, Inc (KLRS) Fair Value & Analysis

Healthcare · US · Market cap $112M

Price$4.47
Fair Value$3.19
Upside-28.6%
Quality95/100
Evidence: Low Range $2.11 – $3.99

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Kalaris Therapeutics, Inc (KLRS) currently trades at $4.47, while our model-based Fair Value estimate is $3.19 — implying the stock looks roughly 28.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Kalaris Therapeutics, Inc (KLRS) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.19 versus a price of $4.47 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of KLRS?
Our 21-model fair value for Kalaris Therapeutics, Inc is $3.19 (as of Jun 25, 2026), built from audited fundamentals. The current price is $4.47.
What is the quality score of KLRS?
Kalaris Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.